Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CLK1 | P49759 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14995363 | 0.77 | TSHR (1.00) | TSHRALDH1A1HTTMAPTCLK1 | |
| SCHEMBL14905758 | 0.76 | LMNA (0.46) | KDM4EEGFRLMNAMEN1KMT2A | |
| SCHEMBL16098263 | 0.75 | ALDH1A1 (0.57) | TSHRALDH1A1HTTGAANPSR1 | |
| SCHEMBL16913890 | 0.74 | HDAC4 (0.48) | HTTGAAKDM4EMAPTLMNA | |
| SCHEMBL27006800 | 0.72 | TSHR (0.69) | TSHRALDH1A1HTTMAPTCLK1 | |
| SCHEMBL20703988 | 0.72 | RAB9A (0.46) | ALDH1A1GAAMAPTLMNAMEN1 | |
| SCHEMBL15986711 | 0.72 | TSHR (0.72) | TSHRALDH1A1KDM4EEGFRSMN1; SMN2 | |
| SCHEMBL30648834 | 0.72 | TSHR (0.72) | TSHRALDH1A1KDM4EEGFRSMN1; SMN2 | |
| SCHEMBL1251926 | 0.71 | LMNA (0.53) | LMNA | |
| SCHEMBL20266375 | 0.71 | HPGD (0.48) | TSHRALDH1A1HTTGAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785438-B2 | Imidazopyridin-2-one derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| EP-2308877-B1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2014-01-22 | — | — | EP | disclosed |
| US-20130338156-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-12-19 | — | — | US | disclosed |
| US-8436012-B2 | Imidazopyridin-2-one derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| EP-2308877-A1 | IMIDAZOPYRIDIN-2-ON DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-20110082138-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082138-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MTOR, MAPKAP1, RICTOR | TSHR 3070/4885ALDH1A1 2312/4885HTT 1471/4885 |
| US-20130338156-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MTOR, MAPKAP1, RICTOR | TSHR 3070/4885ALDH1A1 2312/4885HTT 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.